{
    "clinical_study": {
        "@rank": "138047", 
        "arm_group": [
            {
                "arm_group_label": "2 cycles", 
                "arm_group_type": "Experimental", 
                "description": "2 cycles RTX"
            }, 
            {
                "arm_group_label": "standard 4 cycles", 
                "arm_group_type": "Active Comparator", 
                "description": "standard 4 cycles RTX"
            }
        ], 
        "brief_summary": {
            "textblock": "The project was undertaking by Qilu Hospital of Shandong University and other several\n      well-known hospitals in China. In order to report the efficacy and safety of Rituximab in\n      different frequency for the treatment of adults with refractory immune thrombocytopenia\n      (ITP)."
        }, 
        "brief_title": "A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia \uff08ITP\uff09", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Immune Thrombocytopenia", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "detailed_description": {
            "textblock": "The investigators are undertaking a parallel group, multicentre, randomised controlled trial\n      of 60 refractory ITP adult patients from medical centers in China. One part of the\n      participants are randomly selected to receive rituximab (given intravenously at a dose of\n      375mg/m(2) weekly for 2 weeks, i.e. Day 1, 8; the others are selected to receive standard\n      rituximab treatment (given intravenously at a dose of 375 mg/m(2) weekly for 4 cycles, i.e.\n      Day 1, 8, 15, 22). Platelet count, bleeding and other symptoms were evaluated before and\n      after treatment. Adverse events are also recorded throughout the study. In order to report\n      the efficacy and safety of the combination therapy compared to conventional rituximab\n      therapy for the treatment of adults with refractory ITP."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Meet the diagnostic criteria for immune thrombocytopenia.\n\n          2. Untreated hospitalized patients, may be male or female, between the ages of 18 ~ 80\n             years.\n\n          3. To show a platelet count <30\u00d710^9/L, and with bleeding manifestations.\n\n          4. Willing and able to sign written informed consent.\n\n        Exclusion Criteria:\n\n          1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts\n             within 3 months before the screening visit.\n\n          2. Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine,\n             vincristine, vinblastine, etc) within 3 months before the screening visit.\n\n          3. Received high-dose steroids or IVIG in the 3 weeks prior to the start of the study.\n\n          4. Current HIV infection or hepatitis B virus or hepatitis C virus infections.\n\n          5. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP.\n             Unstable or uncontrolled disease or condition related to or impacting cardiac\n             function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension\n             or cardiac arrhythmia)\n\n          6. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate\n             pregnancy during the study period.\n\n          7. Have a known diagnosis of other autoimmune diseases, established in the medical\n             history and laboratory findings with positive results for the determination of\n             antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct\n             Coombs test.\n\n          8. Patients who are deemed unsuitable for the study by the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137681", 
            "org_study_id": "ITP-RTX2vs4"
        }, 
        "intervention": {
            "arm_group_label": [
                "2 cycles", 
                "standard 4 cycles"
            ], 
            "description": "Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22)  in standard 4 cycles arm", 
            "intervention_name": "Rituximab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "immune thrombocytopenia", 
            "rituximab", 
            "efficacy", 
            "safety"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "houming@medmail.com.cn", 
                "last_name": "Ming Hou, Dr.", 
                "phone": "+86-531-82169114", 
                "phone_ext": "9879"
            }, 
            "facility": {
                "address": {
                    "city": "Jinan", 
                    "country": "China", 
                    "state": "Shandong", 
                    "zip": "250012"
                }, 
                "name": "Qilu Hospital, Shandong University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "2 Cycles Rituximab Compared With Standard Regimen in Management of ITP", 
        "overall_contact": {
            "email": "houming@medmail.com.cn", 
            "last_name": "Ming Hou, Dr.", 
            "phone": "+86-531-82169114", 
            "phone_ext": "9879"
        }, 
        "overall_official": {
            "affiliation": "Shandong University", 
            "last_name": "Ming Hou, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "response rate (CR+R) at the 3rd month from the initial injection of RTX. CR is defined as platelet count \u2265 100\u00d710^9/L, and R is defined as platelet count of >30 \u00d7 10^9/L with a least a doubling of the baseline value.", 
                "measure": "Early Response", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "response rate (CR+R) at the 12st month from the initial injection of RTX. CR is defined as platelet count \u2265 100\u00d710^9/L, and R is defined as platelet count of >30 \u00d7 10^9/L with a least a doubling of the baseline value.", 
                "measure": "Duration Response", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137681"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shandong University", 
            "investigator_full_name": "Ming Hou", 
            "investigator_title": "Professor and Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The type and frequency of therapy associated adverse events", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "1 months"
        }, 
        "source": "Shandong University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shandong University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}